


Novel drug shows promise for alleviating both heart failure and the sleep apnea associated with it

March 30 2023



P2X3-receptor antagonism improves cardiac function in chronic heart failure (CHF) rats. a Representative images of echocardiography in rats submitted to myocardial infarction (MI), before and after 7 weeks of treatment with vehicle or AF-130. Red arrows indicate diastolic ventricular diameter and yellow arrows indicate diastolic ventricular wall thickness. P2X3-receptor antagonism

prevented the reduction of ejection fraction (b) and stroke volume (c) during HF development, and reduced left ventricular (LV) end-systolic volume (d). The parameters were analyzed before MI surgery, three days after MI and after 7 weeks of vehicle (n = 13) or AF-130 (n = 8) administration. IVS: interventricular septum. Data are mean \pm SD. Repeated measures two-way ANOVA, with Student-Newman-Keuls post hoc comparison. *P

Citation: Novel drug shows promise for alleviating both heart failure and the sleep apnea associated with it (2023, March 30) retrieved 27 April 2024 from <https://medicalxpress.com/news/2023-03-drug-alleviating-heart-failure-apnea.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.